JP2018507243A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507243A5
JP2018507243A5 JP2017546704A JP2017546704A JP2018507243A5 JP 2018507243 A5 JP2018507243 A5 JP 2018507243A5 JP 2017546704 A JP2017546704 A JP 2017546704A JP 2017546704 A JP2017546704 A JP 2017546704A JP 2018507243 A5 JP2018507243 A5 JP 2018507243A5
Authority
JP
Japan
Prior art keywords
tradipitant
pharmaceutical composition
composition according
amount
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507243A (ja
JP6891385B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/021015 external-priority patent/WO2016141341A1/en
Publication of JP2018507243A publication Critical patent/JP2018507243A/ja
Publication of JP2018507243A5 publication Critical patent/JP2018507243A5/ja
Application granted granted Critical
Publication of JP6891385B2 publication Critical patent/JP6891385B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546704A 2015-03-04 2016-03-04 トラジピタントによる治療方法 Active JP6891385B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021012356A Division JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法

Publications (3)

Publication Number Publication Date
JP2018507243A JP2018507243A (ja) 2018-03-15
JP2018507243A5 true JP2018507243A5 (enExample) 2019-04-11
JP6891385B2 JP6891385B2 (ja) 2021-06-18

Family

ID=55629110

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017546704A Active JP6891385B2 (ja) 2015-03-04 2016-03-04 トラジピタントによる治療方法
JP2021012356A Pending JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法
JP2023006082A Pending JP2023052486A (ja) 2015-03-04 2023-01-18 トラジピタントによる治療方法
JP2024062811A Withdrawn JP2024074963A (ja) 2015-03-04 2024-04-09 トラジピタントによる治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021012356A Pending JP2021073258A (ja) 2015-03-04 2021-01-28 トラジピタントによる治療方法
JP2023006082A Pending JP2023052486A (ja) 2015-03-04 2023-01-18 トラジピタントによる治療方法
JP2024062811A Withdrawn JP2024074963A (ja) 2015-03-04 2024-04-09 トラジピタントによる治療方法

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3730140B1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR20170122777A (enExample)
CN (2) CN107427502B (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA2978736C (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3265087T (pt) * 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
US11549147B2 (en) * 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3101210A1 (en) 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4110335B1 (en) * 2020-02-25 2025-10-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2023413130A1 (en) 2022-12-21 2025-06-05 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
DK1501809T3 (da) 2002-04-26 2008-05-13 Lilly Co Eli Trizolderivater som tachykininreceptorantagonister
JP4895476B2 (ja) * 2002-04-26 2012-03-14 イーライ リリー アンド カンパニー タキキニン受容体アンタゴニスト
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7381826B2 (en) * 2003-10-24 2008-06-03 Eli Lilly And Company Crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Th1型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
CA2643130A1 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
SI2121610T1 (sl) * 2006-12-20 2014-08-29 Eli Lilly & Company Nove vmesne spojine in postopek, ki je uporaben pri pripravi (2-(1-(3,5-bistrifluorometil-benzil)-5-piridin-4-il-1h-(1,2,3)triazol- 4-il)-piridin-3-il)-(2-klorofenil)-metanona
BR112012003263A2 (pt) 2009-08-14 2015-09-22 Opko Health Inc formulações intravenosas de antagonistas de neuroquinina-1
CN106512010A (zh) 2009-11-18 2017-03-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2931253A1 (en) 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
KR20160023692A (ko) * 2013-06-24 2016-03-03 타이거캣 파마, 인크. 소양증에서의 nk-1 수용체 길항제 세를로피탄트의 용도
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
PT3265087T (pt) * 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
HUE053115T2 (hu) 2015-11-30 2021-06-28 Anacor Pharmaceuticals Inc Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
US11549147B2 (en) * 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Similar Documents

Publication Publication Date Title
JP2024074963A5 (enExample)
AU2023233141B2 (en) Method of treatment with tradipitant
JP2021527092A5 (enExample)
RU2707089C2 (ru) Комбинированная композиция
JP2010523587A5 (enExample)
JP2019517542A5 (enExample)
JP2013541583A5 (enExample)
JP2006513184A5 (enExample)
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
JP2021509395A5 (enExample)
RU2007101686A (ru) Комбинированная композиция
JP2016505050A5 (enExample)
JP2013536837A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
Oettmeier et al. The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects
JP2019535830A5 (enExample)
KR20180074707A (ko) 저 용량 경구 디피리다몰 조성물 및 이의 용도
JP2021530568A5 (enExample)
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
JP6420923B1 (ja) 医薬
JP2022540917A5 (enExample)
JP6878021B2 (ja) トリプタンとアスコルビン酸を含有する医薬組成物
RU2022102184A (ru) Способ лечения с применением традипитанта
JP2024518455A5 (enExample)
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta